Central Sensitivity to Free Triiodothyronine With MAFLD and Its Progression to Liver Fibrosis in Euthyroid Adults
The Journal of Clinical Endocrinology & Metabolism · 18.08.2023 · 108 (9) · e687-e697
DOI: 10.1210/clinem/dgad186 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.03.2023. Verfasst von Heng Wan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan City…. Hauptthemen laut MEDLINE: Triiodothyronine, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Context
Impaired sensitivity to thyroid hormones has been demonstrated to be positively associated with the prevalence of metabolic disorders. However, the relationship between sensitivity to thyroid hormones and metabolic dysfunction–associated fatty liver disease (MAFLD) and liver fibrosis remained unclear.
Objective
We aimed to determine the associations of thyroid hormone sensitivity indices with MAFLD and its progression to liver fibrosis in Chinese euthyroid adults.
Methods
This community-based study included 7906 euthyroid adults. We calculated the thyroid sensitivity indices, including free triiodothyronine to free thyroxine (FT3/FT4) ratio, Thyroid Feedback Quantile-based Index by FT4 (TFQIFT4), and Thyroid Feedback Quantile-based Index by FT3 (TFQIFT3), indicating peripheral and central thyroid hormone sensitivity respectively. Liver steatosis and fibrosis were diagnosed by vibration-controlled transient elastography (VCTE). Multivariable logistic/linear regression and restricted cubic spline (RCS) analysis were conducted.
Results
Compared with participants in the first quartile (Q1), the prevalence of MAFLD was increased by 62% in the fourth quartile (Q4) of FT3/FT4 ratio (OR 1.62; 95% CI [1.38, 1.91]) and by 40% in Q4 of TFQIFT3 (OR 1.40; 95% CI [1.18, 1.65]) (both P < .05). No associations between TFQIFT4 and the prevalence of MAFLD were found. In addition, compared with participants in Q1, the prevalence of liver fibrosis was increased by 45% in Q4 of TFQIFT3 (OR 1.45; 95% CI [1.03, 2.06]) (P < .05) in participants with MAFLD.
Conclusion
Impaired central sensitivity to FT3 was associated with MAFLD and its progression to liver fibrosis. More prospective and mechanism studies are warranted to confirm these conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan City 528308, Guangdong, China.
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Wan, H., Yu, G., Xu, S., Chen, X., Jiang, Y., Duan, H., Lin, X., Ma, Q., Wang, D., Liang, Y., Liu, L., & Shen, J. (2023). Central Sensitivity to Free Triiodothyronine With MAFLD and Its Progression to Liver Fibrosis in Euthyroid Adults. The Journal of Clinical Endocrinology & Metabolism, 108(9), e687-e697. https://doi.org/10.1210/clinem/dgad186
Vancouver
Wan H, Yu G, Xu S, Chen X, Jiang Y, Duan H, et al. Central Sensitivity to Free Triiodothyronine With MAFLD and Its Progression to Liver Fibrosis in Euthyroid Adults. The Journal of Clinical Endocrinology & Metabolism. 2023;108(9):e687-e697. doi:10.1210/clinem/dgad186
BibTeX
@article{Wan2023,
author = {Wan, Heng and Yu, Genfeng and Xu, Sirong and Chen, Xingying and Jiang, Yuqi and Duan, Hualin and Lin, Xu and Ma, Qintao and Wang, Dongmei and Liang, Yongqian and Liu, Lan and Shen, Jie},
title = {Central Sensitivity to Free Triiodothyronine With MAFLD and Its Progression to Liver Fibrosis in Euthyroid Adults},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {9},
pages = {e687--e697},
doi = {10.1210/clinem/dgad186}
}
EUVIMED